Ross Moat's most recent trade in Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A was a trade of 27,594 Share Option done . Disclosure was reported to the exchange on June 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 27,594 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 29.02 per share. | 03 Jun 2025 | 27,594 | 9,415 (0%) | 0% | 29.0 | 800,778 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.35 per share. | 03 Jun 2025 | 27,594 | 37,009 (0%) | 0% | 13.4 | 368,380 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 8,303 | 8,303 | - | - | Performance Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 8,043 | 8,043 | - | - | Performance Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 6,272 | 27,389 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 28.00 per share. | 01 May 2025 | 6,272 | 9,415 (0%) | 0% | 28 | 175,616 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. | 01 May 2025 | 6,272 | 15,687 (0%) | 0% | 17.8 | 111,391 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 5,225 | 5,225 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 4,976 | 4,976 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 28.00 per share. | 01 May 2025 | 3,850 | 9,415 (0%) | 0% | 28 | 107,800 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. | 01 May 2025 | 3,850 | 13,265 (0%) | 0% | 17.8 | 68,376 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 3,850 | 33,661 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 25.21 per share. | 29 Apr 2025 | 64,035 | 9,415 (0%) | 0% | 25.2 | 1,614,322 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 28.02 per share. | 29 Apr 2025 | 23,234 | 9,415 (0%) | 0% | 28.0 | 651,017 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.50 per share. | 29 Apr 2025 | 20,000 | 44,415 (0%) | 0% | 15.5 | 310,000 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2025 | 20,000 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.76 per share. | 29 Apr 2025 | 15,307 | 73,450 (0%) | 0% | 10.8 | 164,703 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2025 | 15,307 | 23,361 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.52 per share. | 29 Apr 2025 | 15,000 | 24,415 (0%) | 0% | 15.5 | 232,800 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2025 | 15,000 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2025 | 13,406 | 27,594 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.35 per share. | 29 Apr 2025 | 13,406 | 22,821 (0%) | 0% | 13.3 | 178,970 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2025 | 8,671 | 21,059 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.10 per share. | 29 Apr 2025 | 8,671 | 31,492 (0%) | 0% | 11.1 | 96,248 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.97 per share. | 29 Apr 2025 | 7,432 | 58,143 (0%) | 0% | 12.0 | 88,961 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2025 | 7,432 | 27,252 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.97 per share. | 29 Apr 2025 | 6,296 | 50,711 (0%) | 0% | 13.0 | 81,659 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2025 | 6,296 | 1,658 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2025 | 1,157 | 37,511 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. | 29 Apr 2025 | 1,157 | 32,649 (0%) | 0% | 17.8 | 20,548 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 20.29 per share. | 21 Apr 2025 | 18,259 | 9,415 (0%) | 0% | 20.3 | 370,475 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 2,477 | 2,477 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 2,477 | 28,401 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.28 per share. | 07 Apr 2025 | 727 | 27,674 (0%) | 0% | 20.3 | 14,744 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 39,364 | 39,364 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 19,657 | 19,657 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 9,828 | 9,828 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,741 | 5,221 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,741 | 26,908 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,611 | 25,167 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,611 | 3,222 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.77 per share. | 01 Apr 2025 | 511 | 25,924 (0%) | 0% | 21.8 | 11,124 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.77 per share. | 01 Apr 2025 | 473 | 26,435 (0%) | 0% | 21.8 | 10,297 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 16.00 per share. | 16 Mar 2025 | 1,118 | 22,854 (0%) | 0% | 16 | 17,888 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 994 | 23,848 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 994 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.61 per share. | 16 Mar 2025 | 292 | 23,556 (0%) | 0% | 22.6 | 6,602 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 26.10 per share. | 15 Jul 2024 | 67,346 | 22,896 (0%) | 0% | 26.1 | 1,757,731 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 36,100 | 36,100 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 29,730 | 18,534 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.10 per share. | 15 Jul 2024 | 29,730 | 65,466 (0%) | 0% | 11.1 | 330,003 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 24,776 | 30,924 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.97 per share. | 15 Jul 2024 | 24,776 | 90,242 (0%) | 0% | 12.0 | 296,569 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 14,000 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.83 per share. | 15 Jul 2024 | 14,000 | 35,736 (0%) | 0% | 8.8 | 123,620 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 6,962 | 6,962 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 4,089 | 22,480 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 2,477 | 4,954 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 1,612 | 4,833 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 15 Jul 2024 | 1,393 | 21,087 (0%) | 0% | 26.7 | 37,249 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 27.12 per share. | 15 Jul 2024 | 1,160 | 21,736 (0%) | 0% | 27.1 | 31,459 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 994 | 994 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 994 | 22,081 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 15 Jul 2024 | 345 | 21,736 (0%) | 0% | 26.7 | 9,225 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 15.65 per share. | 15 Jul 2024 | 211 | 18,391 (0%) | 0% | 15.6 | 3,302 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 36,100 | 36,100 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 6,962 | 11,795 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 5,569 | 5,569 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 2,477 | 9,318 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 2,477 | 17,629 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.90 per share. | 04 Apr 2024 | 1,353 | 16,276 (0%) | 0% | 17.9 | 24,219 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,612 | 4,833 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,612 | 16,032 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.70 per share. | 01 Apr 2024 | 880 | 15,152 (0%) | 0% | 19.7 | 17,336 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2023 | 2,477 | 13,906 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2023 | 2,477 | 7,431 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.71 per share. | 10 Apr 2023 | 1,353 | 12,553 (0%) | 0% | 10.7 | 14,491 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 38,668 | 38,668 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 6,445 | 6,445 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2023 | 2,137 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2023 | 2,137 | 12,596 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 9.56 per share. | 15 Jan 2023 | 1,844 | 10,008 (0%) | 0% | 9.6 | 17,629 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.12 per share. | 15 Jan 2023 | 1,167 | 11,429 (0%) | 0% | 11.1 | 12,977 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2023 | 994 | 11,002 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2023 | 994 | 1,988 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.46 per share. | 15 Jan 2023 | 543 | 10,459 (0%) | 0% | 11.5 | 6,223 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 59,460 | 59,460 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 9,908 | 9,908 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 995 | 8,727 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 995 | 2,982 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.44 per share. | 01 Sep 2022 | 563 | 8,164 (0%) | 0% | 11.4 | 6,441 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 9.56 per share. | 01 Sep 2022 | 360 | 7,732 (0%) | 0% | 9.6 | 3,442 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2022 | 59,460 | 59,460 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2022 | 9,908 | 9,908 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2022 | 2,270 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2022 | 2,270 | 8,612 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.98 per share. | 21 Mar 2022 | 1,240 | 7,372 (0%) | 0% | 11.0 | 13,615 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | ARCALYST General Manager | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2021 | 7,954 | 7,954 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | ARCALYST General Manager | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2021 | 3,977 | 3,977 | - | - | Restricted Share Units |